New Search

If you are not happy with the results below please do another search

1807 search results for:


Impressions of MEDICA 2022 + COMPAMED 2022!

Dear Colleagues, Ladies and Gentlemen: It is done! Those were exciting trade fair days for all of us. From 14 – 17 November 2022, MEDICA and COMPAMED lived up to their transnationally highlighted position as leading information and communication platforms for the medical technology business and its supplier sector with a wealth of innovations and […]


MEDICA 2022 and COMPAMED 2022: International health industry meet-up in Düsseldorf

Notable increase in participation – accompanying programme with many highlights and many prominent visitors Next week sees the return of the date marked in extra thick outline in many yearly calendars of the international health and medical technology industry: From Monday to Thursday (14 to 17 November 2022), the international leading medical trade fair MEDICA […]


Profiling of fatty sweet molecules on cell surfaces

Glycolipids, basically “fatty sweet” molecules, are a relatively unknown group of lipids. A new method developed by an Austrian team led by chemist Evelyn Rampler of the University of Vienna has now provided deeper insights into the functioning of certain glycolipids located on the surfaces of stem cells. The approach presented by the researchers from […]


Biochemists find substance that makes cancer cells “suicidal”

The Peoples’ Friendship University of Russia (RUDN) biochemists have obtained a potential anti-cancer agent. The new substance pro-vokes cancer cells to commit “suicide” and at the same time does not affect healthy cells. The results are published in Molecules [1].


Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset

Ardigen, one of the world’s leading artificial intelligence (AI) companies advancing precision medicine, has announced that it is supporting the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) Consortium with its technology and expertise. The consortium of 10 leading pharmaceutical companies and two non-profit research organizations including the Broad Institute of MIT and Harvard, is focused […]


Edmond de Rothschild Equity Strategies IV acquires a majority stake in Oncodesign Services

Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners have completed the acquisition of a majority stake in Oncodesign Services by Edmond de Rothschild Equity Strategies IV, from its main shareholders, including Philippe Genne, founder of Oncodesign Services.